Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors

Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors

Abstract Background The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the e...

Full description

Bibliographic Details
Main Authors:	Yu‐Qian Sun, Lan‐Ping Xu, Kai‐Yan Liu, Xiao‐Hui Zhang, Chen‐Hua Yan, Jian Jin, Xiao‐Jun Huang, Yu Wang
Format:	Article
Language:	English
Published:	Wiley 2021-04-01
Series:	Cancer Communications
Subjects:	myelodysplastic syndrome cytoreduction hypomethylating agent induction chemotherapy hematopoietic stem cell transplantation best supportive care
Online Access:	https://doi.org/10.1002/cac2.12140

Similar Items

Myelodysplastic syndromes: Where do we stand?
by: Nitin Sood, et al.
Published: (2016-01-01)

Acute Myeloblastic Leukemia and Myelodysplastic Syndrome: Azacitidine for Prophylactic and Preventive Purposes after Allogeneic Hematopoietic Stem Cell Transplantation
by: VN Ovechkina, et al.
Published: (2017-01-01)

The Role of Hypomethylating Agents Prior to Allogeneic Hematopoietic Stem Cells Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: VN Ovechkina, et al.
Published: (2017-07-01)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
by: Abigail Belasen, et al.
Published: (2020-07-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome
by: Sagar S. Patel, et al.
Published: (2020-09-01)

Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome
by: Xiangzong Zeng, et al.
Published: (2021-08-01)

Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
by: Vincent Jachiet, et al.
Published: (2021-05-01)

Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?
by: Blaj Sebastian, et al.
Published: (2017-12-01)

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies
by: Nina Kim, et al.
Published: (2018-08-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction
by: Pratistha Koirala, et al.
Published: (2020-08-01)

Transplante de célula-tronco hematopoética para síndrome mielodisplásica Bone marrow transplantation in myelodysplastic syndromes
by: Daniel G. Tabak, et al.
Published: (2010-05-01)

Quaternary and beyond cytoreduction: An updated and expanded analysis
by: Beryl L. Manning-Geist, et al.
Published: (2021-08-01)

Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease
by: Juan José Segura-Sampedro, et al.
Published: (2020-05-01)

Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia
by: Katie Culos, et al.
Published: (2019-05-01)

THE EXPERIENCE AND RESULTS OF CYTOREDUCTIVE SURGERY AND HIPEC USED IN ADVANCED OVARIAN CANCER
by: Oleksandr Bondar, et al.
Published: (2020-10-01)

ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME
by: Teresa L Field, et al.
Published: (2010-07-01)

The role of cytoreduction surgery in advanced ovarian cancer (review)
by: R K Tandelov, et al.
Published: (2018-03-01)

Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01)

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation
by: Chang Hou, et al.
Published: (2021-08-01)

Adding Value of MRI Over CT in Predicting Peritoneal Cancer Index and Completeness of Cytoreduction
by: Chia-Ni Lin, et al.
Published: (2021-04-01)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report
by: Ebbe Billmann Thorgersen, et al.
Published: (2018-09-01)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
by: Jonathan Pan, et al.
Published: (2020-10-01)

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
by: Adriana C. Gamboa, et al.
Published: (2019-10-01)

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy
by: Jina Yun, et al.
Published: (2021-08-01)

Epididymitis following Cytoreductive Surgery with Intraperitoneal Oxaliplatin Chemotherapy: Two Case Reports
by: Luiza Damian Ribeiro Barbosa, et al.
Published: (2016-02-01)

Comparative study of quality of life, adverse effects after cytoreduction and HIPEC in stage IIIA-IIIC ovarian cancer
by: A. I. Rybin, et al.
Published: (2018-10-01)

Perioperative management and postoperative outcome of patients undergoing cytoreduction surgery with hyperthermic intraperitoneal chemotherapy
by: Hamed Elgendy, et al.
Published: (2019-01-01)

Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report
by: Antoine Ponard, et al.
Published: (2018-07-01)

Serious Hemorrhagic Complications After Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy With Defibrotide in Pediatric Patient With Myelodysplastic Syndrome
by: Alexandra Laberko, et al.
Published: (2020-05-01)

INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY
by: Giuseppe Leone, et al.
Published: (2018-07-01)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
by: Loss Martin, et al.
Published: (2004-06-01)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: our initial experience of implementation and detailed technique
by: Talgat Uskenbayev, et al.
Published: (2019-06-01)

Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study
by: Jiafu Huang, et al.
Published: (2020-09-01)

Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients
by: Anna Weiss, et al.
Published: (2018-04-01)

Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
by: Blair McNamara, et al.
Published: (2021-11-01)

Complete Response for More than 4 Years following Neoadjuvant FOLFOX and Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Patient with Advanced Gastric Cancer with Extensive Peritoneal Carcinomatosis
by: Renata D’Alpino Peixoto, et al.
Published: (2018-05-01)

Cannot write session to /tmp/vufind_sessions/sess_gmud702jraler4oue8ahdr48l6